▁Only ▁one ▁programme ▁has ▁reached ▁the ▁clin ical ▁stage . ▁Work ▁on ▁developing ▁gene ▁ther apy ▁for ▁S MA ▁is ▁also ▁conducted ▁at ▁the ▁Institut ▁de ▁My ologie ▁in ▁Paris ▁and ▁at ▁the ▁University ▁of ▁Oxford . ▁In ▁ 2 0 1 8 , ▁also ▁Bi ogen ▁announced ▁working ▁on ▁a ▁gene ▁ther apy ▁product ▁to ▁treat ▁S MA . ▁ ▁SM N 2 ▁alternative ▁sp lic ing ▁mod ulation ▁▁ ▁This ▁approach ▁a ims ▁at ▁modifying ▁the ▁alternative ▁sp lic ing ▁of ▁the ▁SM N 2 ▁gene ▁to ▁force ▁it ▁to ▁code ▁for ▁higher ▁percentage ▁of ▁full - length ▁SM N ▁protein . ▁Sometimes ▁it ▁is ▁also ▁called ▁gene ▁conversion , ▁because ▁it ▁attempts ▁to ▁convert ▁the ▁SM N 2 ▁gene ▁function ally ▁into ▁SM N 1 ▁gene . ▁ ▁The ▁following ▁sp lic ing ▁mod ul ators ▁have ▁reached ▁clin ical ▁stage ▁development : ▁▁ ▁Bran ap lam ▁( L MI 0 7 0 , ▁N VS - SM 1 ) ▁is ▁a ▁propriet ary ▁small - m ole c ule ▁experimental ▁drug ▁admin ister ed ▁or ally ▁and ▁being ▁developed ▁by ▁Nov art is . ▁ ▁the ▁comp ound ▁remains ▁in ▁phase - II ▁clin ical ▁trial ▁in ▁inf ants ▁with ▁S MA ▁type ▁ 1 ▁while ▁tri als ▁in ▁other ▁patient ▁categories ▁are ▁under ▁development . ▁ ▁Ris di pl am ▁( R G 7 9 1 6 , ▁RO 7 0 3 4 0 6 7 ) ▁is ▁a ▁propriet ary ▁small - m ole c ule ▁drug